Design of the randomized, controlled sequential staged treatment of emphysema with upper lobe predominance (STEP-UP) study

• Verfasst von: Valipour, Arschang [VerfasserIn]
• Verfasst von: Herth, Felix [VerfasserIn]
• Verfasst von: Eberhardt, Ralf [VerfasserIn]
• Titel: Design of the randomized, controlled sequential staged treatment of emphysema with upper lobe predominance (STEP-UP) study
• Verf.angabe: Arschang Valipour, Felix J.F. Herth, Ralf Eberhardt, Pallav L. Shah, Avina Gupta, Robert Barry, Erik Henne, Sourish Bandyopadhyay and Greg Snell
• E-Jahr: 2014
• Jahr: 03 December 2014
• Umfang: 10 S.
• Fussnoten: Gesehen am 09.11.2020
• Titel Quelle: Enthalten in: BMC pulmonary medicine
• Ort Quelle: London : BioMed Central, 2001
• Jahr Quelle: 2014
• Band/Heft Quelle: 14(2014) Artikel-Nummer 190, 10 Seiten
• ISSN Quelle: 1471-2466
• DOI: doi:10.1186/1471-2466-14-190
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1738221695

Abstract

Background: An innovative approach to lung volume reduction (LVR) for emphysema is introduced in the design of the Sequential Segmental Treatment of Emphysema with Upper Lobe Predominance (STEP-UP) trial where vapour ablation is administered bilaterally over the course of two sessions and is used to target only the most diseased upper lobe segments. By dividing the procedure into two sessions, there is potential to increase the total volume treated per patient but reduce volume treated and energy delivered per session. This is expected to correlate with improvements in vapour ablation’s safety and efficacy profiles. Methods: The STEP-UP trial is a randomized, controlled, open-label, 12 month study of patients with upper lobe predominant emphysema (ULPE). The trial compares patients receiving standard medical management alone against patients receiving bilateral vapour ablation in addition to standard medical management. An intended sixty nine subjects will be randomized at a 2:1 (treatment arm:control arm) ratio. Inclusion criteria include a forced expiratory volume in 1 second (FEV1) between 20% and 45% predicted, total lung capacity > 100% predicted, residual volume > 150% predicted, marked dyspnea scoring ≥ 2 on the modified Medical Research Council (mMRC) scale, and PaCO2 ≤ 50 mm Hg. The primary endpoints are the change in FEV1 %predicted and St. George Respiratory Questionnaire (SGRQ) score between the treatment and control arm at 12 months. Adverse events will be monitored as secondary endpoints along with other efficacy outcomes at 6 and 12 months. Discussion: Vapour ablation can reduce lung volume in the presence of collateral ventilation (CV). Due to this ability, it can be used to target specifically the more diseased segments of each upper lobe. Safety and efficacy outcomes are expected to improve by considering which segments to treat along with the volume treated per session and per patient. Trial registration: ClinicalTrials.gov NCT01719263.